The following information is presented for educational purposes only.
Medical Marijuana Inc. provides this information to provide an understanding
of the potential applications of cannabidiol. Links to third party websites
do not constitute an endorsement of these organizations by Medical Marijuana
Inc. and none should be inferred.
Chronic Inflammatory Demyelinating Polyneuropathy is an acquired
inflammatory disorder of the peripheral nerve system that affects about 1-2
per 1000,000 people. Studies have shown marijuana helps manage pain
associated with the disorder and reduces inflammation, thus potentially
limiting the disorder’s progression.
Overview of Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare
peripheral nerve disorder that causes weakness and sensory loss with a loss
of reflexes. The disorder is caused by damage to the myelin sheath covering
Scientists believe that CIDP is caused by a dysfunction in the immune
system, which incorrectly perceives myelin as foreign and attacks it in an
attempt to rid it of the body. Myelin enwraps nerve axon, serving as
insulation so that electrical impulses are able to travel efficiently. Loss
or damage of myelin slows electrical impulses or causes them to become lost.
Symptoms associated with CIDP include numbness, tingling, pain, loss of
reflexes and weakness. Patients commonly experience foot drop and
Treatment efforts for CIDP commonly include the administration of
corticosteroids, which provide anti-inflammatory effects, intravenous immune
globulins, which contain naturally-occurring antibodies, and plasma
exchange, which helps to remove the harmful antibodies contained in the
blood. If CIDP is left untreated, approximately 30% of patients will become
wheelchair dependent. Early detection and treatment is effective at
significantly limiting nerve damage caused by the disorder.
Findings: Effects of Cannabis on Chronic Inflammatory Demyelinating
Studies show the cannabis is an effective therapeutic option for treating
neuropathic pain caused from disorders like CIDP and suggest that
cannabinoid found in cannabis could potentially help limit the disorder’s
Cannabis has demonstrated the ability to significantly lower pain levels in
patients suffering from neuropathic and nociceptive pain, and has even to be
effective against pain that has proven refractory to other treatments (Boychuck,
Goddard, Mauro & Orellana, 2015) (Ware, et al., 2010). Even minimal doses of
cannabis have been shown to significantly reduce neuropathic pain (Wilsey,
et al., 2013). Long-term use of cannabis for pain therapy, studies show, is
safe. After a year of regular use, patients with chronic pain were found to
be at no greater risk of serious adverse effects than non-cannabis users
(Ware, et al., 2015).
Cannabis has been shown to suppress the over activity of the body’s immune
system, suggesting that it may also help in limit the progression of CIDP.
The cannabinoids found in cannabis act upon both the CB1 and CB2 receptors
of the endocannabinoid system, which works to regulate the immune system.
Studies have shown that the administration of tetrahydrocannabinol (THC),
one of the major cannabinoids found in cannabis, can suppress both
inflammatory responses and the immune system to allow the body to recovery
from immune-mediated injuries like CIDP (Nagarkatti, et al., 2009).
States That Have Approved Medical Marijuana for Chronic Inflammatory
Currently, Illinois is
the only state that has approved medical marijuana for the treatment of
Chronic Inflammatory Demyelinating Polyneuropathy. However, Arkansas, New
Mexico and North
Dakota have approved its use
to treat painful peripheral neuropathy and New
approved its use for all neuropathies. In Washington
D.C., any condition can be approved for medical marijuana as long as a
DC-licensed physician recommends the treatment.
Several states have approved
medical marijuana specifically to treat “chronic pain,” a symptom commonly
associated with Chronic Inflammatory Demyelinating Polyneuropathy. These
states include: Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Maryland, Michigan, Montana, New
Mexico, Ohio, Oregon, Pennsylvania, Rhode
Island and Vermont.
The states of Nevada, New
Dakota, Montana, Ohio and Vermont allow
medical marijuana to treat “severe pain.” The states of Arkansas, Minnesota, Ohio, Pennsylvania and Washington have
approved cannabis for the treatment of “intractable pain.”
A number of other states will consider allowing medical marijuana to be used
for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy with
the recommendation from a physician. These states include: California (any
debilitating illness where the medical use of marijuana has been recommended
by a physician), Connecticut (other
medical conditions may be approved by the Department of Consumer
Protection), Massachusetts (other
conditions as determined in writing by a qualifying patient’s physician), Nevada (other
conditions subject to approval), Oregon (other
conditions subject to approval), Rhode
conditions subject to approval), and Washington (any
“terminal or debilitating condition”).
Recent Studies on Cannabis’ Effect on Chronic Inflammatory Demyelinating
Low doses of cannabis were effective at significantly reducing
neuropathic pain and improving sleep.
Low-dose vaporized cannabis significantly improves neuropathic pain.
Using cannabis has been shown to significantly improve neuropathic pain
that had proven refractory to other treatments.
The effectiveness of cannabinoids in the management of chronic
nonmalignant neuropathic pain: a systematic review.
All About CIDP. (n.d.). GBS/CIDP
Retrieved from https://www.gbs-cidp.org/cidp/all-about-cidp/.
Boychuck, D.G., Goddard, G., Mauro, G., and Orellana, M.F. (2015 Winter).
The effectiveness of cannabinoids in the management of chronic nonmalignant
neuropathic pain: a systematic review. Journal
of Oral & Facial Pain and Headache,
Nagarkatti, P., Pandey, R., Rieder, S.A., Hedge, V.L., and Nagarkatti, M.
(2009, October). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal
Ware, M.A., Wang, T., Shapiro, S., and Collet, J.P. (2015, September 15).
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The
Journal of Pain.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/26385201.
Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T.,
Gamsa, A., Bennett, G.J., and Collet, J.P. (2010, October 5). Smoked
cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian
Medical Association Journal,
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., and Donaghe,
H. (2013, February). Low-dose vaporized cannabis significantly improves
neuropathic pain. Journal
►CBD Meds Store
Where and How to Buy CBD Cannabidiol Meds Online
or by Phone
You can order your CBD capsules or salve balm either
online by visiting the PayPal payment links at
CBD Meds Store, or by
phoning your order with credit or debit card details to sales manager
Phillip Fry toll-free 1-866-300-1616 or cell
1-480-310-7970 or emailing